Table 2.

The beneficial effects of different sodium glucose cotransporter-2 inhibitors in the management of diabesity based on recent landmark clinical trials[104-108]

Ref.	Drug molecule	Mean weight reduction in kg (SE/95%CI)	Mean % haemoglobin reduction (95%CI)	Follow-up
Neal et al[104], 2017 (CANVAS)	Canagliflozin	-1.60 (- 1.70 to -1.51)	-0.58 (-0.61 to -0.56)	3.5 yr
Wiviott et al[105], 2019 (DECLARE)	Dapagliflozin	-1.80 (-2.00 to -1.70)	-0.42 (-0.45 to -0.40)	4.2 yr
Häring et al[106], 2014 (EMPA-REG)	Empagliflozin	-1.63 (-2.11 to -1.5) for 10 mg	-0.57 (-0.70 to -0.43) for 10 mg	24 wk
		-2.01 (-2.49 to -1.53) for 25 mg	-0.64 (-0.77 to -0.50) for 25 mg
Rosenstock et al[107], 2018 (VERTIS-MET)	Ertugliflozin	-3.00 (-3.30 to -2.70) for 5 mg	-0.70 (-0.90 to -0.50) for 5 mg	24 wk
		-2.90 (-3.20 to -2.60) for 15 mg	-0.90 (-1.00 to -0.70) for 15 mg
Dagogo-Jack et al[108], 2018 (VERTIS-SITA)	Ertugliflozin	-2.0 (-2.7 to -1.4) for 5 mg	-0.70 (-0.90 to -0.50) for 5 mg	26 wk
		-1.7 (-2.4 to -1.1) for 10 mg	-0.80 (-0.90 to -0.60) for 10 mg

HbA1C: Haemoglobin; CI: Confidence interval.